Lilly raises UK Mounjaro list prices by up to 170%, NHS reimbursement follows
The change affects UK list and NHS reimbursement prices for Mounjaro, not US prices, and it shows how quickly tirzepatide pricing can move in a single market.
Eli Lilly raised UK list prices for Mounjaro (tirzepatide) KwikPen by as much as 170% on September 1, 2025, and the Department of Health and Social Care (DHSC) redetermined NHS reimbursement prices for every strength so pharmacies would not dispense at a loss [1][2].
The 2.5 mg pen rose from £92 to £133, and the 5 mg pen from £92 to £180. The 7.5 mg and 10 mg pens both went from £107 to £255. The 12.5 mg and 15 mg pens rose from £122 to £330, the largest jump in the group at about 170% [1][2]. All figures are for a single 2.4 ml pre-filled disposable pen [1][2].
Lilly said it raised the UK list price after a review, to address pricing inconsistencies compared with other developed countries, including in Europe. The company said it reached an agreement with the NHS at the same time to ensure continued supply and patient access [2].
On the NHS side, DHSC confirmed the redetermined reimbursement prices apply from September 2025 [1]. Community Pharmacy England said it agreed with DHSC that NHS prescriptions for Mounjaro — whether written by brand or generic name — dispensed from September will be reimbursed at the higher list prices, specifically to avoid pharmacy owners dispensing at a loss [2]. The September 2025 Drug Tariff still shows the old list prices; the new list prices are to be updated in the October 2025 Drug Tariff [2].
Private supply is handled separately. Community Pharmacy England said it understands there are growing concerns about Mounjaro pricing and supply arrangements for private services offered by many pharmacies, but its remit covers NHS pharmacy services only, so it cannot address questions about private supply [2]. Lilly has a commercial agreement available to all private providers to support dispensing of private prescriptions; pharmacies that do not dispense private Mounjaro prescriptions are advised not to accept that agreement, and pharmacies that decline it can still access stock for NHS dispensing in the usual way [2]. Lilly said it does not determine the prices private healthcare providers set, and that it is working with them to maintain patient access [2].
Why it matters for patients
Mounjaro is tirzepatide, the same molecule sold in the US as Mounjaro and Zepbound. This is a UK pricing action. It does not set or change US list prices, and no US price changes tied to it have been reported.
Within the UK, the two paths now differ. NHS patients are covered by the redetermined reimbursement prices, which are what pharmacies are paid, not what patients pay at the counter. People paying privately in the UK — a large share of the market for these medicines — face list prices that Lilly raised sharply, and the company says it does not control what private providers charge [2]. How much of the increase reaches private patients has not been reported.
The picture for people in the US is unchanged by this development. What an individual pays depends on insurance coverage, pharmacy and any cash-pay program, all of which operate separately from UK list prices. Whether Lilly has raised or will raise list prices in other countries, including the US, has not been reported.
What happens next
The updated list prices are expected to appear in the October 2025 Drug Tariff, even though the September redetermination already applies to September prescriptions [2]. Whether other countries see similar increases, and whether private UK providers pass the full increase through to patients, has not been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.